Get the Stockscreener App
6.655
0.22%
-0.015
Harvard Bioscience Inc stock is traded at $6.655, with a volume of 15,415.
It is down -0.22% in the last 24 hours and up +12.23% over the past month.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.
See More
Previous Close:
$6.67
Open:
$6.605
24h Volume:
15,415
Relative Volume:
0.76
Market Cap:
$30.30M
Revenue:
$85.53M
Net Income/Loss:
$-9.78M
P/E Ratio:
-3.0316
EPS:
-2.1952
Net Cash Flow:
$1.28M
1W Performance:
+2.86%
1M Performance:
+12.23%
6M Performance:
+20.00%
1Y Performance:
+35.98%
1-Day Range:
$6.51
$6.70
1-Week Range:
$6.05
$6.70
52-Week Range:
$3.755
$9.40
Harvard Bioscience Inc Stock (HBIO) Company Profile
Name
Harvard Bioscience Inc
Sector
Industry
Phone
(508) 893-8999
Address
84 OCTOBER HILL RD, HOLLISTON, MA
Compare HBIO vs ISRG, BDX, ALC, RMD, MDLN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HBIO
Harvard Bioscience Inc
|
6.655 | 28.09M | 85.53M | -9.78M | 1.28M | -2.1952 |
ISRG
Intuitive Surgical Inc
|
394.51 | 141.76B | 11.03B | 3.16B | 3.22B | 8.7251 |
BDX
Becton Dickinson Co
|
183.40 | 50.00B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
74.25 | 35.57B | 10.63B | 819.00M | 1.59B | 1.6577 |
RMD
Resmed Inc
|
224.46 | 32.78B | 5.54B | 1.52B | 1.74B | 10.37 |
MDLN
Medline Inc
|
35.74 | 31.15B | 29.14B | 1.07B | 1.05B | 1.1956 |
Harvard Bioscience Inc Stock (HBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-09-25 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Mar-10-23 | Upgrade | The Benchmark Company | Speculative Buy → Buy |
| Jan-07-21 | Upgrade | The Benchmark Company | Speculative Buy → Buy |
| Dec-09-20 | Initiated | Northland Capital | Outperform |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Jul-08-19 | Downgrade | Janney | Buy → Neutral |
| Jan-24-18 | Reiterated | Janney | Buy |
| Jan-23-18 | Reiterated | The Benchmark Company | Buy |
| Nov-17-16 | Initiated | Singular Research | Buy |
| Jul-28-15 | Initiated | The Benchmark Company | Buy |
View All
Harvard Bioscience Inc Stock (HBIO) Latest News
Benchmark raises Harvard Bioscience stock price target on revenue beat By Investing.com - Investing.com South Africa
HBIO Maintained by Benchmark -- Price Target Raised to $7.50 - GuruFocus
Benchmark raises Harvard Bioscience stock price target on revenue beat - Investing.com
Harvard Bioscience, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:HBIO) 2026-08-12 - Seeking Alpha
Harvard Bioscience, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
HARVARD BIOSCIENCE INC 2026: Revenue $22.73M, EPS ($0.64) — 10-Q Summary - TradingView
Harvard Bioscience (NASDAQ: HBIO) grows Q2 sales but faces higher debt costs - Stock Titan
Harvard Bioscience Inc (HBIO) (Q2 2026) Earnings Call Highlights - GuruFocus
HBIO Looks 66.8% Undervalued on GF Value™ Despite Profitability Challenges - GuruFocus
Harvard Bioscience Inc (HBIO) (Q2 2026) Earnings Call Highlights: Revenue Surges 11% and ... - Yahoo Finance
Harvard Bioscience Releases Q2 2026 Financial Results - AlphaStreet
Earnings call transcript: Harvard Bioscience tops Q2 2026 forecasts, raises outlook - Investing.com Nigeria
HBio Q2 2026 slides: revenue up 11%, China growth drives guidance raise - Investing.com Nigeria
Harvard Bioscience beats Q2 estimates and raises 2026 revenue guidance - Yahoo Finance
Harvard Bioscience beats estimates, raises 2026 guidance - Investing.com
Harvard Bioscience Raises Full-Year 2026 Revenue Guidance After Strong Second-Quarter Growth - Minichart
Why is Harvard Bioscience stock gaining today? By Investing.com - Investing.com Canada
Is Harvard Bioscience Inc (HBIO) Undervalued After Q2 Earnings B - GuruFocus
Harvard Bioscience beats estimates, raises 2026 guidance By Investing.com - Investing.com South Africa
Harvard Bioscience: Q2 Earnings Snapshot - marketscreener.com
Harvard Bioscience Q2 revenue rises on telemetry demand, lifts 2026 outlook - TradingView
Harvard Bioscience Q2 Revenue Rises 11 Percent to $22.7 Million - Quiver Quantitative
Harvard Bioscience Announces Second Quarter 2026 Financial Results - marketscreener.com
Harvard Bioscience (HBIO) grows Q2 2026 sales but stays in loss - Stock Titan
BRIEF-Harvard Bioscience Q2 Net Income USD -2.91 Million - TradingView
Harvard Bioscience, Inc. Provides Earnings Guidance for the Third Quarter of 2026 - marketscreener.com
Harvard Bioscience Inc (HBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Harvard Bioscience Inc expected to post a loss of 21 cents a shareEarnings Preview - TradingView
Harvard Bioscience Q2 Results: Earnings Call Set for August 11 - scanx.trade
Harvard Bioscience Schedules Second Quarter 2026 Earnings Conference Call for August 11, 2026 at 8:00 AM ET - The Manila Times
Harvard Bioscience Schedules Second Quarter 2026 Earnings Conference Call for August 11, 2026 ... - Caledonian Record
Harvard Bioscience Inc (HBIO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Harvard Bioscience Inc (HBIO) Cash Flow - TradingKey
Harvard Bioscience Inc (HBIO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Harvard Bioscience Inc (HBIO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Harvard Bioscience Inc (HBIO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Harvard Bioscience Inc (HBIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
HBIO|Harvard Bioscience Inc|Price:6.000|Chg%:-0.190 - TradingKey
Harvard Bioscience, Inc. Revenue Breakdown – MUN:HBI0 - TradingView
Harvard Bioscience, Inc. Revenue Breakdown – LS:A423J5 - TradingView
Harvard Bioscience, Inc. Revenue Breakdown – NASDAQ:HBIO - TradingView
Harvard Bioscience, Inc. Revenue Breakdown – LSX:A423J5 - TradingView
HBIO Stock Price, Quote & Chart - ChartMill
Harvard Bioscience Inc (HBIO) Institutional Confidence - TradingKey
HBIO Q2'26 Earnings: revenue estimate is 21.45M USD - TradingView
Harvard Bioscience focuses on life science instruments as investors weigh long-term demand - ad-hoc-news.de
Harvard Bioscience (HBIO) Slips 4.5% as Selling Pressure Tests Key SupportETF Inflow Streak - po-news-eg.net
Harvard Bioscience focuses on lab equipment growth - Ad-hoc-news.de
Harvard Bioscience (HBIO) Hovers Near Support Amid Low-Volume TradingBollinger Walk - dars.gov.et
Harvard Bioscience | SD: Specialized disclosure report - Moomoo
Harvard Bioscience, Inc. Actuals & Estimates (NASDAQ:HBIO) - TradingView
Harvard Bioscience Inc Stock (HBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.90%
1.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):